Has unpredictability become the new norm for pharma and life sciences?

Nigel Layton, Global Head of Pharma and Life Sciences explains that technology is a core strategic pillar for life sciences business models. Artificial intelligence is already delivering tangible benefits across the sector. It is improving manufacturing processes, enhancing efficiency and supporting innovation in product development and drug production. As organisations become more familiar with AI, investment continues to accelerate, driven by the opportunities it offers to improve speed, quality and scalability.

Large multinational organisations are assessing geopolitical risk at scale, evaluating where tariffs are having the greatest impact, reviewing manufacturing footprints and aligning growth strategies accordingly. Manufacturing location, regulatory access and market prioritisation are increasingly interconnected.

Mid‑sized and growing businesses face a different, but equally complex, set of challenges. Many are now private‑equity backed and expanding internationally, particularly into the US market. While the geopolitical environment presents hurdles, these organisations are continuing to invest and grow, demonstrating resilience despite heightened complexity.

What’s changing?

• Global uncertainty is influencing manufacturing, sourcing and pricing decisions.
• Supply chains are under renewed pressure, with limited flexibility.
• Digital transformation is accelerating, increasing both opportunity and risk.

Watch the interview with Nigel to hear how life sciences leaders are strengthening resilience, leveraging technology and managing supply‑chain complexity in an increasingly uncertain global environment.